
David Planchard/oncostream.com
Apr 11, 2025, 17:57
David Planchard: Beating Durvalumab Monotherapy Post-CRT in Unresectable Stage III NSCLC
David Planchard, Thoracic Oncologist, Professor at University Paris Saclay and Head of Thoracic Cancer Group at Gustave Roussy, shared this post on LinkedIn:
“A higher-than-expected step towards beating durvalumab monotherapy post CRT unresectable stage III NSCLC…PACIFIC 9 ?
Great discussions at the ISCO meeting in Cairo !”
More posts featuring David Planchard.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 12, 2025, 19:25
Apr 12, 2025, 19:14
Apr 12, 2025, 19:10
Apr 12, 2025, 18:52
Apr 12, 2025, 18:48